

Efficient Palladium-Catalyzed Cross-Coupling of Highly Acidic Substrates, Nitroacetates

Alison E. Metz, Simon Berritt, Spencer D. Dreher, and Marisa C. Kozlowski**

Table of Contents

General Methods	S2
Procedures for Parallel Microscale Experimentation	S2-S5
Formation of Nitroarylacetates	S5-S9
References	S9
Spectral Data	S10-S22

General Methods. Unless otherwise noted, all non-aqueous reactions were carried out under an atmosphere of dry argon in dry glassware and all solvents and reagents were HPLC grade and used without further purification. When necessary, solvents and reagents were dried prior to use. Moisture sensitive reagents were added via syringe. Toluene was distilled from CaH_2 and degassed with freeze-pump-thaw cycles (3 x). THF was distilled from NaH/benzophenone prior to use. Flash column chromatography was performed on EM Reagents Silica Gel 60 (230-400). Analytical thin layer chromatography (TLC) was performed on EM Reagents 0.25 mm silica-gel 254-F plates. Visualization was accomplished with UV light and/or KMnO_4 stain.

^1H NMR and ^{13}C spectra were recorded on a Bruker AM-500 (500 MHz) spectrometer. Chemical shifts are reported from the solvent resonance peak (CDCl_3 7.27 ppm). Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, bs = broad singlet, m = multiplet), coupling constants, and number of protons. Mass spectra were obtained on a high resonance VG autospec with an ionization mode of either CI or ES. IR spectra were taken on an ASI ReactIR 1000FT-IR spectrometer. Melting points were obtained on a Thomas Scientific Unimelt apparatus and are uncorrected. All yields reported refer to isolated yields unless otherwise indicated, and the product purity was determined by ^1H NMR. Compounds described in the literature were characterized by comparison of their spectra to reported data. New compounds were also characterized by high resolution mass.

Procedures for Parallel Microscale Experimentation. Reactions of ethyl nitroacetate with bromobenzene, *o*-bromotoluene or pyridyl halide.

The following procedure is representative of the high-throughput experimentation reactions described in this publication. The ligands (2 μmol) were dosed into the 96-well reactor 1-mL vial as solutions (50 μL of a 0.04 M solution in THF or toluene depending on the solubility of the ligand). Plates of these ligands may be plated in advance of the screen; the solvent is removed by evacuation on a Genevac, and the plates are stored in the glovebox. Palladium source (1.0 μmol Pd, 50 μL of a 0.02 M solution in THF) was then added to the reaction vials and this was evacuated to dryness on a Genevac or JKem-blow-down block. Base (24 μmol , 25 mg/mL slurry in THF) was then added to the ligand/catalyst mixture, and this was evacuated to dryness on a Genevac or JKem-blow-down block. A parylene stir-bar was added to each reaction. The aryl halide (20 μmol /reaction), ethyl nitroacetate (40 μmol /reaction) were then dosed together in the reaction solvents (100 μL of a 0.20 M and 0.40 M solution respectively). The vials were then sealed and heated at 80 $^\circ\text{C}$ for 18 h. After cooling to ambient temperature, the reaction mixtures were evacuated to dryness on a Genevac or JKem-blow-down block. The residues were diluted with a solution of internal standard and acetic acid in MeCN (2 μmol biphenyl or *tert*-butyl biphenyl, 60 μmol acetic acid, 500 μL of solution), and the contents were stirred. Into a separate 96-well plate LC block was added 750 μL of MeCN and then 20 μL of the diluted reaction mixtures. The 96-well plate LC block was then sealed with a polypropylene 1 mL cap mat. The reactions were analyzed using an Agilent Technologies 1200 series HPLC with a 96-well plate auto-sampler.

High throughput experimentation (HTE) #1 consisted of one 96-well plate in toluene and one in

1,2-dimethoxyethane (DME) and screened the variables listed below. Top leads are represented in Table 1. All table results are listed in order of least to most product formation as measured against an internal standard (IS).

Ligands

X-Phos: 2-(Cy₂P)-2',4',6'-*i*-Pr-biphenyl
 JohnPhos: 2-(*t*-Bu₂P)-biphenyl
 RuPhos: 2-(Cy₂P)-2',6'-*i*-PrO-biphenyl
 cataCXium A: Ad₂Pn-Bu
 [HP(*t*-Bu)₃]BF₄
 dtbpf: 1,1'-(*t*-Bu₂P)-ferrocene
 dppf: 1,1'-Ph₂P-ferrocene
 dppp: 1,3-(Ph₂P)-Pr
 DPEPhos: (2-Ph₂PPh)₂O
 (R)-BINAP
 SL-J009-1 : (R)-(S)-cy₂PF-Pt-Bu₂
t-Bu XPhos: 2-(*t*-Bu₂P)-2',4',6'-*i*-Pr-biphenyl [HP(Cy)₃]BF₄
 S-Phos: 2-(Cy₂P)-2',6'-MeO-biphenyl
 DavePhos: 2-(Cy₂P)-2'-(Me₂N)-biphenyl
 BrettPhos: 2-(Cy₂P)-3,6-MeO-2',4',6'-*i*-Pr-biphenyl
 Q-Phos: 1'-(*t*-Bu₂P)-1,2,3,4,5-Ph-ferrocene
 AmPhos [A-^{ta}Phos]: 1-(*t*-Bu₂P)-4-(Me₂N)-Ph
 (o-Tol)₃P
 dippf: 1,1'-(*i*-Pr₂P)-ferrocene
 dppb: 1,4-(Ph₂P)-Bu
 XantPhos: 4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene
 Me₄ *t*-Bu XPhos: 2-(*t*-Bu₂P)-3,4,5,6-Me-2',4',6'-*i*-Pr-biphenyl
 cataCXium PtB: 2-(*t*-Bu₂P)-1-Ph-pyrrole

Bases

CsCO₃, CsHCO₃, NaOAc, K₃PO₄

Palladium Sources

[allylPdCl]₂, Pd₂dba₃ • CHCl₃

Table 1. HTE #1: Ligand screen. Selected data from conditions that gave product.

Palladium Source	Ligand	Base	Solvent	Product/IS
Pd ₂ dba ₃ • CHCl ₃	BrettPhos	K ₃ PO ₄	toluene	0.13
Pd ₂ dba ₃ • CHCl ₃	Me ₄ <i>t</i> -Bu XPhos	K ₃ PO ₄	toluene	0.45
Pd ₂ dba ₃ • CHCl ₃	BrettPhos	Cs ₂ CO ₃	toluene	0.83
(PdallylCl) ₂	Me ₄ <i>t</i> -Bu XPhos	CsHCO ₃	DME	1.04
(PdallylCl) ₂	<i>t</i> -Bu Xphos	Cs ₂ CO ₃	DME	1.82
(PdallylCl) ₂	Me ₄ <i>t</i> -Bu XPhos	Cs ₂ CO ₃	DME	1.84
(PdallylCl) ₂	<i>t</i> -Bu Xphos	K ₃ PO ₄	DME	3.03
Pd ₂ dba ₃ • CHCl ₃	Me ₄ <i>t</i> -Bu XPhos	CsHCO ₃	toluene	3.73
Pd ₂ dba ₃ • CHCl ₃	Me ₄ <i>t</i> -Bu XPhos	Cs ₂ CO ₃	toluene	4.52
(PdallylCl) ₂	<i>t</i> -Bu Xphos	CsHCO ₃	DME	5.08
Pd ₂ dba ₃ • CHCl ₃	<i>t</i> -Bu Xphos	CsHCO ₃	toluene	6.91

High throughput experimentation (HTE) #2 consisted of 2 identical 96-well plates. One was stirred at 75 °C and the other was stirred at 110 °C to study temperature effects. Variables are listed below. Top leads are represented in Table 2 and 3. All of the reactions in the screens are represented pictorially in Figures 25. Figure 4 appears in the main text.

Ligands

t-Bu XPhos: 2-(*t*-Bu₂P)-2',4',6'-*i*-Pr-biphenyl

Me₄ *t*-Bu XPhos: 2-(*t*-Bu₂P)-3,4,5,6-Me-2',4',6'-*i*-Pr-biphenyl

Base

Cs₂CO₃

CsHCO₃

Palladium Sources

t-Bu XPhos Preformed¹: [2-(*t*-Bu₂P)-2',4',6'-*i*-Pr-1,1'-biphenyl][2-(2-aminoethyl)phenyl]PdCl
(only with ligand *t*-Bu XPhos)

[PdallylCl]₂

Pd(OAc)₂

Pd₂dba₃

Solvents

toluene

tetrahydrofuran (THF)

t-amyl alcohol (*t*-AmylOH)

1,2-dimethoxyethane (DME)

cyclopentyl methyl ether (CPME)

1,4-dioxane

Table 2. HTE #2: Selected data from screen at 75 °C.

Pd	Ligand	Base	Solvent	Product/IS
Pd ₂ dba ₃	Me ₄ <i>t</i> -Bu XPhos	CsHCO ₃	dioxane	1.89
Pd(OAc) ₂	Me ₄ <i>t</i> -Bu XPhos	Cs ₂ CO ₃	<i>t</i> -AmylOH	2.02
Pd(OAc) ₂	<i>t</i> -Bu XPhos	CsHCO ₃	DME	2.24
Pd(OAc) ₂	<i>t</i> -Bu XPhos	Cs ₂ CO ₃	CPME	2.28
Pd(OAc) ₂	Me ₄ <i>t</i> -Bu XPhos	CsHCO ₃	dioxane	2.28
<i>t</i> -Bu XPhos Preformed	<i>t</i> -Bu XPhos	Cs ₂ CO ₃	toluene	2.38
<i>t</i> -Bu XPhos Preformed	<i>t</i> -Bu XPhos	Cs ₂ CO ₃	<i>t</i> -AmylOH	2.74


Table 3. HTE #2: Selected data from screen at 110 °C.

Pd	Ligand	Base	Solvent	Product/IS
Pd(OAc) ₂	Me ₄ <i>t</i> -Bu XPhos	Cs ₂ CO ₃	CPME	1.28
Pd(OAc) ₂	<i>t</i> -Bu XPhos	CsHCO ₃	toluene	1.29
Pd(OAc) ₂	Me ₄ <i>t</i> -Bu XPhos	CsHCO ₃	DME	1.34
Pd ₂ dba ₃	<i>t</i> -Bu XPhos	CsHCO ₃	CPME	1.39
Pd(OAc) ₂	Me ₄ <i>t</i> -Bu XPhos	Cs ₂ CO ₃	<i>t</i> -AmylOH	1.51
Pd ₂ dba ₃	<i>t</i> -Bu XPhos	CsHCO ₃	toluene	1.57
Pd(OAc) ₂	Me ₄ <i>t</i> -Bu XPhos	Cs ₂ CO ₃	THF	2.37


Formation of Nitroarylacetates.

Method A. In a glove-box, to an oven-dried microwave vial was added $\text{Pd}_2(\text{dba})_3 \cdot \text{CHCl}_3$ (6.5 mg, 6.3 μmol), *t*-Bu XPhos (10.6 mg, 25.0 μmol), and CsHCO_3 (58.0 mg, 0.30 mmol). Next, a solution of ethyl nitroacetate (0.50 mmol, 0.63 mL of 0.80 M solution in toluene) and additional toluene (0.63 mL) were added to give a heterogenous reaction mixture. At this point, the vial was sealed using a biotag cap equipped with a septum and removed from the glovebox. Aryl bromide (0.25 mmol) was added via syringe. The solution was then heated at 75-80 °C and stirred vigorously for 18 h. After cooling, the reaction mixture was diluted with EtOAc (1 mL) and acidified with HCl (2 mL, 1 M). The layers were separated and the aqueous layer extracted with additional EtOAc (5 x 1 mL). The combined organic layers were concentrated *in vacuo*. The residue was chromatographed (5:95 EtOAc:hexanes) to afford the desired product.


Method B. In a glove-box, to an oven-dried microwave vial was added $\text{Pd}_2(\text{dba})_3 \cdot \text{CHCl}_3$ (9.8 mg, 9.50 μmol), *t*-Bu XPhos (16.1 mg, 38.0 μmol), and CsHCO_3 (88.0 mg, 0.427 mmol). Next, a solution of ethyl nitroacetate (0.38 mmol, 0.48 mL of 0.80 M solution in toluene) and additional toluene (1.42 mL) were added to give a heterogenous reaction mixture. At this point, the vial was sealed using a biotag cap equipped with a septum and removed from the glovebox. Aryl bromide (0.570 mmol) was added via syringe. The solution was then heated at 75-80 °C and stirred vigorously for 18 h. After cooling, the reaction mixture was diluted with EtOAc (1 mL) and acidified with HCl (2 mL, 1 M). The layers were separated and the aqueous layer extracted with additional EtOAc (5 x 1 mL). The combined organic layers were concentrated *in vacuo*. The residue was chromatographed (5:95 EtOAc:hexanes) to afford the desired product.




Ethyl 2-nitro-2-phenylacetate. Using method A of the general procedure the title compound was obtained as yellow oil (48.6 mg, 93%). In addition to the above scale, this reaction was performed on large scale using bromobenzene (379 μL , 3.60 mmol), ethyl nitroacetate (800. μL , 7.20 mmol), $\text{Pd}_2(\text{dba})_3 \cdot \text{CHCl}_3$ (37.0 mg, 36.0 μmol , 2 mol %), *t*-Bu XPhos (61.0mg, 144 μmol), and CsHCO_3 (838 mg, 4.32 mmol) to yield the title compound (627 mg, 83%). Spectral data were in agreement with reported literature values.²




Ethyl 2-nitro-2-(*p*-tolyl)acetate. Using method A of the general procedure, the title compound was obtained as a yellow oil (44.1 mg, 79%). ¹H NMR (500 MHz, CDCl_3) δ 7.39 (d, *J* = 8.0 Hz, 2H), 7.28 (d, *J* = 8.0 Hz, 2H), 6.14 (s, 1H), 4.39-4.28 (m, 2H), 2.41 (s, 3H), 1.31 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (125 MHz, CDCl_3) δ 164.4, 141.3, 129.98, 129.97, 126.3, 90.9, 63.4, 21.5, 14.1; IR (film) 2989, 2927, 1746, 1568, 1367, 1259, 1205, 1020 cm^{-1} ; HRMS-ESI (*m/z*): [*M* – *H*]⁺ calcd for $\text{C}_{11}\text{H}_{12}\text{NO}_4$, 222.0766; found, 222.0764.




Ethyl 2-(naphthalen-2-yl)-2-nitroacetate. Using method A of the general procedure, the title compound was obtained as a yellow oily solid (49.9 mg, 77%). ^1H NMR (500 MHz, CDCl_3) δ 7.98 (d, J = 1.2 Hz, 1H), 7.95 (d, J = 8.6 Hz, 1H), 7.90 (d, J = 7.5 Hz, 2H), 7.62-7.55 (m, 3H), 6.34 (s, 1H), 4.43-4.26 (m, 2 H), 1.32 (t, J = 7.1 Hz, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 164.3, 134.3, 133.1, 130.8, 129.3, 128.7, 128.04, 127.98, 127.2, 126.4, 126.0, 91.2, 63.6, 14.1; IR (film) 2989, 1746, 1568, 1359, 1197, 1020 cm^{-1} ; HRMS-ESI (m/z): $[\text{M} - \text{H}]^-$ calcd for $\text{C}_{14}\text{H}_{12}\text{NO}_4$, 258.0766; found, 258.0757.




Ethyl 2-nitro-2-(4-(trifluoromethyl)phenyl)acetate. Using method A of the general procedure, the title compound was obtained as a yellow oil (40.3 mg, 71%). ^1H NMR (500 MHz, CDCl_3) δ 7.74 (d, J = 8.2 Hz, 2H), 7.65 (d, J = 8.2 Hz, 2H), 6.23 (s, 1H), 4.41-4.29 (m, 2H), 1.31 (t, J = 7.1 Hz, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 163.4, 132.9 (q, J = 32.9 Hz), 132.5, 130.5, 126.3 (q, J = 3.7 Hz), 123.6 (q, J = 272.7 Hz), 90.1, 63.8, 13.9; IR (film) 2989, 2927, 1753, 1568, 1328, 1213, 1166, 1128, 1066, 1020 cm^{-1} ; HRMS-ESI (m/z): $[\text{M} - \text{H}]^-$ calcd for $\text{C}_{11}\text{H}_9\text{F}_3\text{NO}_4$, 276.0472; found, 276.0475.




Ethyl 2-(4-acetylphenyl)-2-nitroacetate. Using method A of the general procedure, the title compound was obtained as a yellow oil (60.3 mg, 96%). ^1H NMR (500 MHz, CDCl_3) δ 8.01 (d, J = 8.4 Hz, 2H), 7.60 (d, J = 8.4 Hz, 2H), 6.24 (s, 1H), 4.36-4.28 (m, 2H), 2.61 (s, 3H), 1.28 (t, J = 7.1 Hz, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 197.4, 163.5, 138.7, 133.3, 130.3, 128.9, 90.2, 63.7, 26.8, 13.9; IR (film) 3059, 2989, 1753, 1692, 1568, 1359, 1205, 1020 cm^{-1} ; HRMS-ESI (m/z): $[\text{M} - \text{H}]^-$ calcd for $\text{C}_{12}\text{H}_{12}\text{NO}_5$, 250.0715; found, 250.0723.




Ethyl 2-(4-methoxyphenyl)-2-nitroacetate. Using method B of the general procedure, the title compound was obtained as a yellow oil (44.3 mg, 74%). ^1H NMR (500 MHz, CDCl_3) δ 7.43 (d, J = 8.8 Hz, 2H), 6.97 (d, J = 8.8 Hz, 2H), 6.23 (s, 1H), 4.37-4.29 (m, 2H), 3.85 (s, 3H), 1.31 (t, J = 7.2 Hz, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 164.2, 161.3, 131.3, 120.9, 114.4, 90.3, 63.1, 55.3, 13.8; IR (film) 2981, 2935, 2858, 1746, 1560, 1367, 1251, 1213, 1027 cm^{-1} ; HRMS-ESI (m/z): $[\text{M} - \text{H}]^-$ calcd for $\text{C}_{11}\text{H}_{12}\text{NO}_5$, 238.0715; found, 238.0715.




Ethyl 2-(6-methoxynaphthalen-2-yl)-2-nitroacetate. 2-Bromo-6-methoxynaphthalene was prepared according to literature procedure.³ Using method B of the general procedure, the title compound was obtained as an orange oily solid (83.5 mg, 76%). ¹H NMR (500 MHz, CDCl₃) δ 7.98 (d, *J* = 1.7 Hz, 1H), 7.81 (d, *J* = 8.8 Hz, 1H), 7.80 (d, *J* = 8.8 Hz, 1H), 7.56 (dd, *J* = 1.7, 8.7 Hz, 1H), 7.22 (dd, *J* = 2.5, 8.7 Hz, 1H), 7.17 (d, *J* = 2.5 Hz, 1H), 6.30 (s, 1H), 4.41-3.97 (m, 2 H), 3.95 (s, 3H), 1.32 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 164.6, 159.2, 135.7, 130.5, 130.1, 128.4, 128.0, 126.6, 124.1, 120.0, 105.8, 91.2, 63.5, 55.6, 14.1; IR (film) 3059, 2989, 2912, 2842, 1746, 1560, 1267, 1197, 1027 cm⁻¹; HRMS-ESI (*m/z*): [M – H][–] calcd for C₁₅H₁₄NO₅, 288.0872; found, 288.0862.




Ethyl 2-nitro-2-(3-(trifluoromethyl)phenyl)acetate. Using method A of the general procedure, the title compound was obtained as a yellow oil (55.4 mg, 80%). ¹H NMR (500 MHz, CDCl₃) δ 7.78 (m, 2H), 7.74 (d, *J* = 7.9 Hz, 1H), 7.63 (t, *J* = 7.9, 1H), 6.22 (s, 1H), 4.41-4.32 (m, 2H), 1.31 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 163.4, 133.4, 131.2 (q, *J* = 33.1 Hz), 129.90, 129.88, 127.8 (q, *J* = 3.6 Hz), 127.0 (q, *J* = 3.7 Hz), 123.6 (q, *J* = 272.9 Hz), 90.2, 63.9, 14.0; IR (film) 2989, 1753, 1568, 1328, 1259, 1166, 1128, 1020 cm⁻¹; HRMS-ESI (*m/z*): [M – H][–] calcd for C₁₁H₉F₃NO₄, 276.0484; found, 258.0494.




Ethyl 2-(1-methyl-1H-indol-5-yl)-2-nitroacetate. 5-Bromo-1-methylindole was prepared according to literature procedure.⁴ Using method A of the general procedure, the title compound was obtained as a yellow oil (62.4 mg, 95%). ¹H NMR (500 MHz, CDCl₃) δ 7.76 (d, *J* = 1.6 Hz, 1H), 7.40 (d, *J* = 8.5 Hz, 1H), 7.35 (dd, *J* = 1.6, 8.5 Hz, 1H), 7.13 (d, *J* = 3.1 Hz, 1H), 6.56 (d, *J* = 3.1 Hz, 1H), 6.29 (s, 1H), 4.41-4.28 (m, 2 H), 3.82 (s, 3H), 1.31 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) 165.0, 137.7, 130.5, 128.7, 123.6, 122.9, 120.1, 110.1, 102.0, 91.9, 63.2, 33.2, 14.1; IR (film) 2981, 2927, 1746, 1560, 1359, 1189, 1020 cm⁻¹; HRMS-ESI (*m/z*): [M + Na]⁺ calcd for C₁₃H₁₄N₂O₄Na, 285.0851; found, 285.0857.




Ethyl 2-(2-methoxyphenyl)-2-nitroacetate. Using method A of the general procedure, the title compound was obtained as a yellow oil (41.0 mg, 69%). ¹H NMR (500 MHz, CDCl₃) δ 7.47 (dt, *J* = 1.6, 7.9 Hz, 1H), 7.36 (dd, *J* = 1.6, 7.7 Hz, 1H), 7.05 (t, *J* = 7.7 Hz, 1H), 6.97 (d, *J* = 7.9 Hz, 1H), 6.64 (s, 1H), 4.40-4.33 (m, 2H), 3.87 (s, 3H), 1.33 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 164.9, 157.8, 132.4, 130.3, 121.1, 118.0, 111.2, 85.3, 63.2, 55.9, 14.1; IR (film) 2927, 2858, 1753, 1568, 1367, 1205, 1112, 1020 cm⁻¹; HRMS-ESI (*m/z*): [M + Na]⁺ calcd for C₁₁H₁₃NO₅Na, 262.0691; found, 262.0688.




Ethyl 2-(benzofuran-5-yl)-2-nitroacetate. 5-Bromobenzofuran was prepared according to literature procedure.⁵ Using method B of the general procedure, the title compound was obtained as a yellow oil (26.0 mg, 58%). ¹H NMR (500 MHz, CDCl₃) δ 7.79 (d, *J* = 1.8 Hz, 1H), 7.71 (d, *J* = 2.2 Hz, 1H), 7.59 (d, *J* = 8.6 Hz, 1H), 7.44 (d, *J* = 8.6, 1.8 Hz, 1H) 6.83 (d, *J* = 2.2 Hz, 1H), 6.28 (s, 1H), 4.42-4.31 (m, 2H), 1.32 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 164.4, 156.0, 146.6, 128.3, 126.1, 123.8, 123.6, 112.3, 107.0, 91.1, 63.5, 14.1; IR (film) 2929, 2850, 2363, 1753, 1568, 1305, 1205, 1128, 1027 cm⁻¹; HRMS-ESI (*m/z*): [M – H][–] calcd for C₁₂H₁₀NO₅, 248.0559; found, 248.0563.




Ethyl 2-(4-chlorophenyl)-2-nitroacetate. Using method A of the general procedure, the title compound was obtained as a yellow oil (38.3 mg, 63%). ¹H NMR (500 MHz, CDCl₃) δ 7.45 (s, 4H), 6.13 (s, 1H) 4.40-4.30 (m, 2H), 1.31 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 163.7, 137.3, 131.4, 129.5, 127.4, 90.1, 63.7, 14.0; IR (film) 2989, 2927, 2858, 1753, 1568, 1359, 1205, 1097, 1020 cm⁻¹; HRMS-ESI (*m/z*): [M – H][–] calcd for C₁₀H₉NO₄Cl, 242.0220; found, 242.0211.




Diethyl 2,2'-(1,4-phenylene)bis(2-nitroacetate). In addition to the preceding desired product, the title compound was also obtained as a yellow oil (13.3 mg, 16%). ¹H NMR (500 MHz, CDCl₃) δ 7.63 (s, 4H), 6.20 (s, 2H) 4.42-4.29 (m, 4H), 1.31 (t, *J* = 7.1 Hz, 6H); ¹³C NMR (125 MHz, CDCl₃) δ 163.5, 131.5, 130.8, 90.3, 63.8, 14.0; IR (film) 2927, 2858, 1753, 1568, 1359, 1205, 1097, 1020 cm⁻¹.



Benzyl 2-nitro-2-phenylacetate. Method A of the general procedure was employed with benzyl nitroacetate (97.6 mg, 0.500 mmol), which was prepared according to literature procedure.⁵ The title compound was obtained as a yellow oil (64.6 mg, 95%). ¹H NMR (500 MHz, CDCl₃) δ 7.49-7.43 (m, 5H), 7.40-7.30 (m, 5H), 6.22 (s, 1H), 5.33 (d, *J* = 12.2 Hz, 1H) 5.28 (d, *J* = 12.2 Hz, 1H) ¹³C NMR (125 MHz, CDCl₃) δ 163.9, 134.3, 130.9, 130.0, 129.2, 129.0, 128.9, 128.8, 128.5, 90.9, 68.9; IR (film) 3043, 2966, 2970, 1753, 1560, 1359, 1290, 1197 cm⁻¹; HRMS-ESI (*m/z*): [M – H][–] calcd for C₁₅H₁₂NO₄, 270.0766; found, 270.0768.



tert-Butyl 2-nitro-2-phenylacetate. Method A of the general procedure was employed with *tert*-butyl nitroacetate (80.6 mg, 0.500 mmol), which was prepared according to literature procedure.⁵ The title compound was obtained as a yellow oil (21.7 mg, 98%). The spectral data were in agreement with reported literature values.⁶



Methyl 2-nitro-2-phenylacetate. Method A of the general procedure was utilized with *tert*-butyl nitroacetate (59.5 mg, 0.500 mmol), which was prepared according to literature procedure.⁵ The title compound was obtained as a yellow oil (25.6 mg, 53%). The spectral data were in agreement with reported literature values.⁶

Reference

1. a) Kinzel, T.; Zhang, Y.; Buchwald, S. L. *J. Am. Chem. Soc.* **2010**, *132*, 14073-14075. b) Biscoe, M. R.; Fors, B. P.; Buchwald, S. L. *J. Am. Chem. Soc.* **2008**, *130*, 6686-6687.
2. Lehr, F.; Gonnerman, J.; Seebach, D. *Helv. Chim. Acta* **1979**, *62*, 2258-2275.
3. Wiel, M. K. J. ter ; Feringa, B. L. *Synthesis* **2005**, *11*, 1789-1796.
4. Shieh, W.-C.; Dell, S.; Bach, A.; Repič, O.; Blacklock, T.J. *J. Org. Chem.* **2003**, *68*, 1954-1957.
5. Suzuki, H.; Tsutsui, H.; Kano, A.; Katoh, S.; Morita, T.; Matsuda, K.; Iibuchi, N.; Ogawa, M. *Heterocycles* **1997**, *45*, 1657-1662.
6. González, D. F.; Brand, J. P.; Waser, J. *Chem. Eur. J.* **2010**, *16*, 9457-9461.

